What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Susan M. Domchek mainly investigates Breast cancer, Internal medicine, Cancer, Oncology and Gynecology.
In her research on the topic of Breast cancer, Estrogen receptor is strongly related with Gene mutation.
Her research integrates issues of Germline mutation, Surgery and Pathology in her study of Internal medicine.
Her Cancer research incorporates themes from Genetic testing, Cancer research and Bioinformatics.
The various areas that Susan M. Domchek examines in her Oncology study include Olaparib, Tolerability, Metastatic breast cancer, Case-control study and Prostate cancer.
The Gynecology study combines topics in areas such as Male breast cancer, Epidemiology, Obstetrics, Prospective cohort study and Cancer prevention.
Her most cited work include:
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (1797 citations)
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer (1152 citations)
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (1004 citations)
What are the main themes of her work throughout her whole career to date?
Her scientific interests lie mostly in Breast cancer, Internal medicine, Oncology, Cancer and Ovarian cancer.
Her Breast cancer research incorporates elements of Cancer research, Gynecology, Family history and Single-nucleotide polymorphism.
Her study in Gynecology is interdisciplinary in nature, drawing from both Risk factor and Obstetrics.
The concepts of her Internal medicine study are interwoven with issues in Germline mutation and Olaparib.
Her Oncology research integrates issues from PARP inhibitor, Chemotherapy, Gene mutation and Hazard ratio.
Her Cancer study integrates concerns from other disciplines, such as CHEK2, Prospective cohort study, Odds ratio and Penetrance.
She most often published in these fields:
- Breast cancer (61.11%)
- Internal medicine (53.77%)
- Oncology (46.23%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (53.77%)
- Oncology (46.23%)
- Breast cancer (61.11%)
In recent papers she was focusing on the following fields of study:
Her primary scientific interests are in Internal medicine, Oncology, Breast cancer, Cancer and Genetic testing.
The Internal medicine study combines topics in areas such as Polygenic risk score, Olaparib and Cancer susceptibility.
Her work is dedicated to discovering how Oncology, Germline are connected with Somatic cell and other disciplines.
She has researched Breast cancer in several fields, including CHEK2, Ejection fraction, Family history and Gene mutation.
Susan M. Domchek interconnects Germline mutation, Li–Fraumeni syndrome and Proportional hazards model in the investigation of issues within Cancer.
Her Genetic testing study combines topics in areas such as Usual care, Randomized controlled trial, MEDLINE, Bioinformatics and Genetic counseling.
Between 2017 and 2021, her most popular works were:
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (129 citations)
- Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations (100 citations)
- Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 1.2020 featured updates to the NCCN guidelines (94 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
The scientist’s investigation covers issues in Internal medicine, Oncology, Breast cancer, Cancer and Olaparib.
Her studies deal with areas such as Random assignment and Anxiety as well as Internal medicine.
The various areas that Susan M. Domchek examines in her Oncology study include Progressive disease, Chemotherapy, Ovarian cancer, Prospective cohort study and Complex segregation analysis.
She is studying Cancer Family, which is a component of Breast cancer.
Her Cancer study incorporates themes from Germline mutation, Computational biology and Proportional hazards model.
Her work carried out in the field of Olaparib brings together such families of science as Cancer research, Metastatic breast cancer, PARP inhibitor and Durvalumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
